AI assistant
REPLIGEN CORP — Director's Dealing 2022
Aug 4, 2022
30826_dirs_2022-08-04_98bb862c-28fa-40fb-a656-6b3d2b17aa8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2022-08-03
Reporting Person: Bylund James (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-03 | Common Stock | M | 2000 | $94.33 | Acquired | 11733 | Direct |
| 2022-08-03 | Common Stock | S | 2000 | $240.40 | Disposed | 9733 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-03 | Stock Option (Right to Buy) | $94.33 | M | 2000 | Disposed | 2030-04-01 | Common Stock (2000) | Direct |
Footnotes
F1: $240.40 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.36 to $240.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: 4,000 of the shares underlying the option have vested. The remaining shares vest as follows: 2,000 shares on April 1, 2023, April 1, 2024 and April 1, 2025.